Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00922181
• Date of registration: 01/06/2009
• Prospective Registration: No
• Primary sponsor: University Hospital, Gasthuisberg
• Public title: Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer LiverMWA1
• Scientific title: Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible
• Date of first enrolment: August 2008
• Target sample size: 19
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00922181
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
• Phase: N/A

Countries of recruitment

Belgium

Contacts

• Name: Baki Topal, MD, PhD
• Affiliation: Universitaire Ziekenhuizen Leuven

Key inclusion & exclusion criteria

Inclusion Criteria:

- Unresectable metastatic liver cancer

- No invasion of major biliary structures

- No invasion of major vascular structures

- ASA score < 4

- WHO score 0-1

- Pre-operative chemotherapy is allowed

Exclusion Criteria:

- Resectable liver metastases

- Life expectancy less than 3 months

- Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic
instruments or other metal materials

- Coagulopathy with platelet count less than 50000

- Active infectious disease

- Age below 18 years

- Pregnancy of breastfeeding



Age minimum: 18 Years
Age maximum: 90 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Liver Neoplasms

Intervention(s)

Device: Radiofrequency ablation

Device: Microwave ablation

Primary Outcome(s)

Variability of ablation diameters [Time Frame: within the first 7 days and 3 months after surgery]

Secondary ID(s)

kulasMWA1

Source(s) of Monetary Support

Please refer to primary and secondary sponsors